Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Semaglutide B · 1 trial · 1 indication
Measured in hours nanomoles per liter (h \* nmol/L).
Measured in nanomoles per liter(nmol/L).
Measured in hours.
Measured in hours.
| Arm | Type | Description |
|---|---|---|
| Sequence 1: Semaglutide J then Semaglutide L | EXPERIMENTAL | Participants will receive subcutaneously semagutide B in treatment period 1 followed by oral semaglutide J then semaglutide L in treatment period 2. |
| Sequence 2: Semaglutide L then Semaglutide J | EXPERIMENTAL | Participants will receive subcutaneously semagutide B in treatment period 1 followed by oral semaglutide L then semaglutide J in treatment period 2. |
| Sequence 3: Semaglutide J then Semaglutide M | EXPERIMENTAL | Participants will receive subcutaneously semagutide B in treatment period 1 followed by oral semaglutide J then semaglutide M in treatment period 2. |
| Sequence 4: Semaglutide M then Semaglutide J | EXPERIMENTAL | Participants will receive subcutaneously semagutide B in treatment period 1 followed by oral semaglutide M then semaglutide J in treatment period 2. |
| Sequence 5: Semaglutide J then Semaglutide N | EXPERIMENTAL | Participants will receive subcutaneously semagutide B in treatment period 1 followed by oral semaglutide J then semaglutide N in treatment period 2. |
| Sequence 6: Semaglutide N then Semaglutide J | EXPERIMENTAL | Participants will receive subcutaneously semagutide B in treatment period 1 followed by oral semaglutide N then semaglutide J in treatment period 2. |
| Name | Type | Description |
|---|---|---|
| Semaglutide B | DRUG | Semaglutide B will be administered subcutaneously. |
| Semaglutide J | DRUG | Semaglutide J will be administered as oral tablets. |
| Semaglutide L | DRUG | Semaglutide L will be administered as oral tablets. |
| Semaglutide M | DRUG | Semaglutide M will be administered as oral tablets. |
| Semaglutide N | DRUG | Semaglutide N will be administered as oral tablets. |
Inclusion Criteria: 1. Male. 2. Age 18-64 years (both inclusive) at the time of signing the informed consent. 3. Body mass index (BMI) between 22.0 and 31.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening. 4. Considered to be generally healthy based on the medical history, physica...
Semaglutide B is an investigational small molecule being studied for Type 2 Diabetes Mellitus and in healthy volunteers. It is in Phase 1 clinical development by Novo Nordisk A/S. The drug is not approved and remains under investigation for its potential use in these metabolic conditions.
Semaglutide B is being developed by Novo Nordisk A/S, a biopharmaceutical company traded on the stock exchange under the ticker NVO. The company is conducting early-stage clinical trials to evaluate this investigational small molecule for Type 2 Diabetes Mellitus.
Semaglutide B is currently in Phase 1 clinical development. It has completed three Phase 1 trials with a total enrollment of 90 participants. The drug is investigational and has not received approval, though it has been granted accelerated approval designation by the FDA.
Semaglutide B has completed three Phase 1 trials: NCT05232708, a comparability study of two forms of semaglutide in healthy volunteers in the UK; NCT05689099, a comparability study of two concentrations in the US; and NCT06642584, a study of new protein-based tablets in healthy men in Canada.
Semaglutide B is a distinct investigational drug being developed by Novo Nordisk. While it shares a name with the approved medication semaglutide, Semaglutide B is a separate small molecule in early clinical development for Type 2 Diabetes Mellitus and has not been approved for any use.